Skip to content
Open access

MYC targeted de novo binders impair tumor growth

Oct 2026 · bioRxiv · 0 citations
Medicine Biology

TL;DR

A panel of de novo designed intracellular protein binders that target conserved functional regions of MYC with nanomolar affinity, remodel MYC complexes and interaction networks in cells, suppress proliferation across MYC-dependent cancer models, and are depleted from orthotopic pancreatic tumors in vivo are developed.

Abstract

MYC is one of the most frequently dysregulated oncogenic drivers across many cancers, yet direct therapeutic targeting has remained difficult because its function is mediated by disordered regions and transient protein-protein interactions. Here we design proteins that bind epitopes within regions of MYC whose sequence is conserved between human and mouse, including intrinsically disordered motifs required for oncogenic activity. In vitro, the designs bind MYC with nanomolar affinity and in cells they engage MYC, disrupt interactions with MAX, and remodel MYC-associated protein complexes. Expression of the binders decreases cell proliferation across diverse MYC-dependent hematopoietic, liver, pancreatic, and patient-derived tumor models, and in an orthotopic pancreatic cancer model, binder-expressing tumor cells were selectively depleted. This work establishes de novo protein design as a generalizable strategy to therapeutically target intrinsically disordered transcription factors. One-sentence summary We developed a panel of de novo designed intracellular protein binders that target conserved functional regions of MYC with nanomolar affinity, remodel MYC complexes and interaction networks in cells, suppress proliferation across MYC-dependent cancer models, and are depleted from orthotopic pancreatic tumors in vivo.

Read PDF

Similar papers

Review Open access Nov 2026

Recent advances and future directions in targeting MYCN: From undruggable to druggable.

MYCN is a member of the MYC family of transcription factors and a potent oncogenic driver across neural crest, neuroectodermal, and neuroendocrine malignancies, including neuroblastoma, where MYCN amplification remains one of the most powerful molecular predictors of treatment failure and poor survival. MYCN has long b...

Kyabeth Torres-rodriguez, Angelle L. Brown, John M. Maris et al. · 0 citations
Open access Oct 2026

NEAT1 remodeling rewires the MYC degradation pathway

It is demonstrated that the functional output of a scaffold lncRNA is encoded in its sub-domain architecture rather than bulk transcript levels, establishing domain-specific RNA targeting as a tractable strategy to rewire protein turnover pathways for otherwise undruggable oncogenes.

Hagoon Jang, B. K. Suh, Fei-Jie Zhang et al. · 0 citations
Open access Nov 2026

Targeting a MYC-directed metabolic vulnerability sensitizes tyrosine kinase inhibitor therapy with selectivity

A key strategy for precision therapy lies in identifying and targeting tumor cell-specific metabolic vulnerabilities to develop effective combination treatments. In this study, we demonstrate that vandetanib, a multi-kinase inhibitor, acts as a potent transcriptional repressor of the serine synthesis pathway (SSP) in...

Yan Zhou, Yin-Yin Xie, Fu-Hui Wang et al. · 0 citations
Review Open access Oct 2026

Targeted Degradation of the c-Myc Oncoprotein: Molecular Mechanisms, Technological Platforms, and Therapeutic Perspectives in Oncology

Background/Objectives: The c-Myc oncoprotein is a master regulator of cell cycle progression, cellular metabolism, and ribosome biogenesis, and its dysregulation occurs in more than 70% of human malignancies. Its intrinsically disordered structure and absence of deep hydrophobic binding pockets have historically limite...

T. Lupanova, Georgii P. Georgiev, A. S. Sobolev · 0 citations
Open access Nov 2026

Domain-alteration chimeras rewire oncogenic complexes in prostate cancer.

Transcriptional addiction to the androgen receptor (AR) underlies metastatic castration-resistant prostate cancer1, in which AR maintains oncogenic programs through domain-specific interactions with the acetyltransferases p300 and CBP (collectively p300/CBP)2. Here we describe a novel therapeutic modality, domain-alter...

Jie Luo, Jian-Zhang Yang, J. Tien et al. · 0 citations
Open access Nov 2026

Targeting mutant p53 aggregates in pancreatic cancer using an autophagy-targeting chimera

Protein aggregation is increasingly recognized as a fundamental feature of cancer biology, particularly in tumors experiencing chronic proteotoxic stress. TP53 is one of the most frequently mutated genes in human cancers, and many cancer-associated missense mutations promote p53 misfolding and amyloid-like aggreg...

Su-Jin Lee, Tri Pham, Min-Ju Lee et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.